Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden

1. Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49(15):3262–73. doi: 10.1016/j.ejca.2013.04.024 23751569

2. Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014;111(5):965–9. doi: 10.1038/bjc.2014.362 24992581

3. Andrae B, Kemetli L, Sparén P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100(9):622–9. doi: 10.1093/jnci/djn099 18445828

4. Lönnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1354–61. doi: 10.1158/1055-9965.EPI-12-0162 22665576

5. Lynge E, Rygaard C, Baillet MV-P, Dugué P-A, Sander BB, Bonde J, et al. Cervical cancer screening at crossroads. APMIS. 2014;122(8):667–73. doi: 10.1111/apm.12279 25046198

6. Hakama M. Effect of population screening for carcinoma of the uterine cervix in Finland. Maturitas. 1985;7(1):3–10. 4021826

7. Dillner J. Cervical cancer screening in Sweden. Eur J Cancer. 2000;36(17):2255–9. 11072216

8. Palmer TJ, McFadden M, Pollock KGJ, Kavanagh K, Cuschieri K, Cruickshank M, et al. HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data. Br J Cancer. 2016;114(5):576–81. doi: 10.1038/bjc.2015.473 26794278

9. Castañón A, Landy R, Cuzick J, Sasieni P. Cervical Screening at Age 50–64 Years and the Risk of Cervical Cancer at Age 65 Years and Older: Population-Based Case Control Study. PLOS Med. 2014;11(1):e1001585. doi: 10.1371/journal.pmed.1001585 24453946

10. Elfström KM, Arnheim-Dahlström L, von Karsa L, Dillner J. Cervical cancer screening in Europe: Quality assurance and organisation of programmes. Eur J Cancer. 2015;51(8):950–68. doi: 10.1016/j.ejca.2015.03.008 25817010

11. Lynge E, Lönnberg S, Törnberg S. Cervical cancer incidence in elderly women—biology or screening history? Eur J Cancer. 2017;74:82–8. doi: 10.1016/j.ejca.2016.12.021 28335890

12. Wijngaarden WJV, Duncan ID. Rationale for stopping cervical screening in women over 50. BMJ. 1993;306(6883):967–71. 8490472

13. Armaroli P, Gallo F, Bellomi A, Ciatto S, Consonni D, Davi D, et al. Do women ≥50 years of age need as much screening as women <50 years after they have had negative screening results? Br J Cancer. 2008;99(2):239–44. doi: 10.1038/sj.bjc.6604455 18594534

14. Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in preventing cervical cancer among older women. Cancer Causes Control. 2013;24(9):1653–60. doi: 10.1007/s10552-013-0239-4 23744043

15. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003;89(1):88–93. doi: 10.1038/sj.bjc.6600974 12838306

16. Swedish National Cervical Screening Registry. 2015 [cited 2015 Jun 24]. Available from: http://www.nkcx.se/index_e.htm.

17. Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Michaëlsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31(2):125–36. doi: 10.1007/s10654-016-0117-y 26769609

18. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish Cancer Register—a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33. doi: 10.1080/02841860802247664 18767000

19. Statistics Sweden. Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym). Stockholm: Statistics Sweden; 2017 [cited 2017 May 18]. Available from: http://www.scb.se/lisa-en.

20. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim J-L, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):450.

21. Socialstyrelsen. Dödsorsaksregistret. Stockholm: Socialstyrelsen; 2017 [cited 2017 May 18]. Available from: http://www.socialstyrelsen.se/register/dodsorsaksregistret.

22. Statistics Sweden. Stockholm: Statistics Sweden; 2015 [cited 2015 Jun 15]. Available from: http://www.scb.se/en/

23. Wang J, Andrae B, Sundström K, Ström P, Ploner A, Elfström KM, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ. 2016;352:i276. doi: 10.1136/bmj.i276 26869597

24. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244–56. doi: 10.1093/aje/kwp107 19494242

25. Dignam JJ, Zhang Q, Kocherginsky MN. The use and interpretion of competing risks regression models. Clin Cancer Res. 2012;18(8):2301–8. doi: 10.1158/1078-0432.CCR-11-2097 22282466

26. Ekbom A. The Swedish Multi-generation Register. In: Dillner J, editor. Methods in Biobanking. Totowa (New Jersey): Humana Press; 2011. pp. 215–20.

27. Agresti A. Categorical data analysis. 3rd ed. Wiley Series in Probability and Statistics. Hoboken (New Jersey): John Wiley & Sons; 2013.

28. Andrae B, Andersson TM-L, Lambert PC, Kemetli L, Silfverdal L, Strander B, et al. Screening and cervical cancer cure: population based cohort study. BMJ. 2012;344:e900. doi: 10.1136/bmj.e900 22381677

29. Leval A, Sundström K, Ploner A, Dahlström LA, Widmark C, Sparén P. Assessing perceived risk and STI prevention behavior: a national population-based study with special reference to HPV. PLoS ONE. 2011;6(6):e20624. doi: 10.1371/journal.pone.0020624 21674050

30. Cuzick J, Clavel C, Petry K-U, Meijer, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5):1095–101. doi: 10.1002/ijc.21955 16586444

31. Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315–24. doi: 10.1093/jnci/djq001 20157096

32. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res. 2008;68(21):8813–24. doi: 10.1158/0008-5472.CAN-08-1380 18974124

33. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJF, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524–32. doi: 10.1016/S0140-6736(13)62218-7 24192252

34. Kulasingam SL, Havrilesky LJ, Ghebre R, Myers ER. Screening for cervical cancer: a modeling study for the US Preventive Services Task Force. J Low Genit Tract Dis. 2013;17(2):193–202. doi: 10.1097/LGT.0b013e3182616241 23519288

35. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42. doi: 10.1309/AJCPTGD94EVRSJCG 22431528

36. Strander B, Hällgren J, Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. BMJ. 2014;348:f7361. doi: 10.1136/bmj.f7361 24423603